RESUMO
Human papillomavirus (HPV) infections are the most common sexually transmitted diseases leading to genital warts. Developing lesions start off as small papules, which then grow larger and protrude, eventually coalescing into plaque-like formations. The aim of this study was to evaluate the efficacy of diode laser coagulation as a treatment for genital warts relative to their number, size, localisation, and recurrence rate. Altogether, 45 patients were evaluated in this study. Patients were initially assigned to one of two groups, depending on the size and number of their genital warts, and received a maximum of two laser treatments. Patients were assessed up to three months after intervention. A cure was defined as the complete removal of condylomata. In Group I, 84% of the patients (21/25) were free of recurrence after three months (last follow-up visit). In Group II, 60% of the patients were free of recurrence after three months (12/20 patients); 25% after the first and 35% after the second treatment. Overall, a cure rate of 73% was achieved (33/45 patients). By splitting the laser treatment for multiple, extensive, and/or coalescing genital warts into two sessions, thereby being less destructive to the surrounding tissue, it was possible to achieve comparable cure rates between the two groups. This study indicates that laser treatment is an effective therapy option. Further studies including larger patient cohorts are necessary to ultimately confirm the advantages of laser treatment.
Assuntos
Condiloma Acuminado/cirurgia , Condiloma Acuminado/virologia , Terapia a Laser/métodos , Lasers Semicondutores/uso terapêutico , Infecções Sexualmente Transmissíveis/cirurgia , Adulto , Estudos de Coortes , Feminino , Seguimentos , Alemanha , Humanos , Masculino , Pessoa de Meia-Idade , Infecções por Papillomavirus/diagnóstico , Infecções por Papillomavirus/cirurgia , Estudos Prospectivos , Recidiva , Medição de Risco , Arábia Saudita , Infecções Sexualmente Transmissíveis/prevenção & controle , Fatores de Tempo , Resultado do TratamentoAssuntos
Eritrodermia Ictiosiforme Congênita/tratamento farmacológico , Ictiose Lamelar/tratamento farmacológico , Ceratolíticos/uso terapêutico , Erros Inatos do Metabolismo Lipídico/tratamento farmacológico , Doenças Musculares/tratamento farmacológico , Ácidos Nicotínicos/uso terapêutico , Adolescente , Feminino , Humanos , Eritrodermia Ictiosiforme Congênita/fisiopatologia , Ictiose Lamelar/fisiopatologia , Erros Inatos do Metabolismo Lipídico/fisiopatologia , Doenças Musculares/fisiopatologia , Creme para a Pele/uso terapêutico , Tomografia de Coerência Óptica , Perda Insensível de ÁguaAssuntos
Atresia das Cóanas/genética , Fenda Labial/genética , Fissura Palatina/genética , Displasia Ectodérmica/genética , Anormalidades do Olho/genética , Pálpebras/anormalidades , Mutação , Dermatopatias/genética , Pele/patologia , Fatores de Transcrição/genética , Proteínas Supressoras de Tumor/genética , Atresia das Cóanas/diagnóstico , Fenda Labial/diagnóstico , Fissura Palatina/diagnóstico , Análise Mutacional de DNA , Displasia Ectodérmica/diagnóstico , Anormalidades do Olho/diagnóstico , Feminino , Predisposição Genética para Doença , Humanos , Lactente , Recém-Nascido , Fenótipo , Dermatopatias/diagnósticoAssuntos
Vesícula , Epidermólise Bolhosa , Doenças Periodontais , Transtornos de Fotossensibilidade , Pioderma , HumanosAssuntos
Carcinoma Basocelular/tratamento farmacológico , Fotoquimioterapia/métodos , Neoplasias Cutâneas/tratamento farmacológico , Tomografia de Coerência Óptica/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Ácido Aminolevulínico/análogos & derivados , Ácido Aminolevulínico/uso terapêutico , Carcinoma Basocelular/diagnóstico por imagem , Carcinoma Basocelular/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fármacos Fotossensibilizantes/uso terapêutico , Projetos Piloto , Neoplasias Cutâneas/diagnóstico por imagem , Neoplasias Cutâneas/patologiaRESUMO
Treatment of children diagnosed with atopic dermatitis (AD) is an art. Age-dependent barrier function, skin physiology, body surface:weight ratio, the compliance of patient and caregivers, and legal considerations related to the license status of topical and systemic drugs must be considered. Mild to moderate AD can usually be treated sufficiently with a personalized regimen of emollients and topical anti-inflammatory therapy consisting of topical corticosteroids (TCSs) or topical calcineurin inhibitors. Emollients containing bacterial lysates, tailored wet wrap regimen, and proactive therapy with tacrolimus ointment or some TCSs are new developments in the field. Severe AD may need systemic therapy, but all currently available systemic agents for severe AD are either not licensed for children or not advisable on the long term, or both. Therapeutic patient education based on structured, interactive sessions with patients or caregivers and a multidisciplinary team is highly effective. This publication summarizes the current therapeutic options used in the pediatric AD population.
